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Patients on multiple medications are at increased risk for adverse drug events. While physicians can
reduce this risk by regularly reviewing the side-effect proﬁles of their patients’ medications, this process
can be time-consuming. We created a decision support system designed to expedite reviewing potential
adverse reactions through information visualization. The system includes a database containing 16,340
unique drug and side-effect pairs, representing 250 common medications. A numeric score is assigned
to each pair reﬂecting the strength of association between drug and effect. Based on these scores, the sys-
tem generates graphical adverse reaction maps for any user-selected combination of drugs. A study com-
paring speed and accuracy of retrieving side-effect data using this tool versus UpToDate demonstrated a
60% reduction in time to complete a query (61 s vs. 155 s, p < 0.0001) with no decrease in accuracy. These
ﬁndings suggest that information visualization can signiﬁcantly expedite review of potential adverse
drug events.
 2009 Elsevier Inc. All rights reserved.1. Introduction
Adverse drug events are a well-recognized cause of patient
morbidity and increased health care costs in the United States
[1,2]. Patients taking multiple medications are at increased risk
for such events [3,4]. This risk can be reduced, however, if physi-
cians regularly review the adverse reaction proﬁles of their pa-
tients’ medications [5,6]. As the number of drugs increases,
however, so too does the time required to review all of the poten-
tial side-effects [7,8].
Multiple studies have shown that the expected time to complete
a query is a major factor in physicians’ failure to pursue answers to
clinical questions [9–11]. Even when information resources are
readily available, clinicians may forgo searches that are expected
to require more than 2 min to complete [12]. Some have even sug-
gested that in the busy hospital setting this time is closer to 30 s
[13]. Thus, patients on complex drug regimens are doubly disad-
vantaged. They are at increased risk for an adverse event, yet their
physicians may be less likely to perform a thorough review of their
medications due to the lengthy time required. As the number of
medications grows, this inverse relationship is further exacerbated.
Clearly a need exists to reduce the time and effort required of phy-
sicians to review the adverse reaction proﬁles of their patients’ll rights reserved.
0 W 10th Street, Suite 2000,drugs. Ideally, the physician effort-curve would be ﬂat, where
increasing the number of drugs would not signiﬁcantly affect the
time required to complete a medication review. We are unaware
of any solutions to date that have achieved this goal.
Current drug information resources have several limitations
when it comes to retrieving adverse reaction data. First, they are de-
signed primarily for the sequential lookup of medications, where
only one drug can be reviewed at a time. Second, the presentation
of the results is often complex, requiring scanning and searching
of text and tables toﬁnd itemsof importance [14].While someappli-
cations, such as Epocrates, have condensed side-effect results to in-
clude only the most serious and common effects, this convenience
comes at the expense of losing important details regarding the fre-
quency of speciﬁc reactions. Finally, once all the information about
each drug has been retrieved and interpreted, physicians must rely
on theirmemory (or scribbled notes) to organize the collective ﬁnd-
ings into a coherent answer to their original question. Whether
searching for a particular reaction or just reviewing the most com-
moneffects of a drug regimen, the doctormust iterate through these
time-consuming steps before making an informed clinical decision.
In this paper, we introduce Rxplore, a decision support system
speciﬁcally tailored to the evaluation of adverse reactions in pa-
tients on multiple medications. Rxplore aims to address the above
limitations and reduce the time and effort required to review com-
plex drug regimens. We describe the system’s goals, key compo-
nents, and development process. We then present a study
comparing its speed and accuracy to that of a more traditional
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sion of the study’s implications and the applicability of the Rxplore
model to other clinical domains.2. Methods
2.1. Rxplore development
Our primary goals for the system were to (1) allow the simulta-
neous lookup of adverse reaction proﬁles for multiple medications;
(2) provide results in an easily interpretable fashion without sacri-
ﬁcing detail; and (3) reduce demands on physician memory by pre-
senting data in a consolidated format.
Multiple medication lookup is not a new concept. It has been
employed in numerous online applications (e.g., Epocrates, Med-
scape) for the purpose of identifying drug–drug interactions.
Users enter a list of medications, and the system returns any pairs
of drugs with known interactions. Creating such systems is
straightforward because the data model for drug interactions is
simple: a one-to-one relationship between two medications causes
a particular effect.
In contrast, adverse reactions present a more complex data
model for several reasons. First, a single drug can cause hundreds
of effects at varying frequencies and levels of severity. Second, sim-
ilar effects may be described using different terms (e.g., sedation,
somnolence, sleepiness). Thirdly, the data themselves may come
from numerous sources, including clinical trials and post-market-
ing reports. Finally, descriptions of adverse reaction frequency
may be quantitative (‘‘occurs in 12% of patients”), semi-quantita-
tive (‘‘occurs frequently”), or qualitative (‘‘was reported”). These
highly variable and non-speciﬁc descriptions result in a complex
set of information for even a single drug, much less an entire reg-
imen. Thus, simultaneously retrieving adverse reactions for multi-
ple medications offers no intrinsic value unless the complexity of
the data is also addressed.2.2. Creation of a standardized adverse reaction knowledge base
In developing Rxplore, we sought to harmonize the side-effect
data model. We ﬁrst selected 250 commonly used medications,
based on national and local dispensing patterns. We then retrieved
the Food and Drug Administration-approved Structured Product
Labels (SPL’s) for these medications from the DailyMed website
[15]. For each SPL, we extracted adverse event data using a combi-
nation of manual and natural language processing techniques.
We began by isolating the text found in the ‘‘Adverse Reactions”
section of each SPL using XML section identiﬁers (speciﬁcally, code
‘‘34084-4” of the LOINC code system). We then manually divided
this section into tables and paragraphs. Tables were converted to
tab-delimited format and column order was adjusted so that pla-
cebo data was consistently located in the ﬁnal column. These ta-
bles were then processed using regular expressions to extract
side-effect name, drug frequency, and placebo frequency. Each
side-effect was then mapped to a corresponding preferred term
in the Medical Dictionary of Regulatory Activities (MedDRA) Ver-
sion 11.1. This use of preferred terms provided consistency of ad-
verse event naming across multiple labels, so for example the
terms ‘‘hyponatremia,” ‘‘decreased serum sodium,” and ‘‘blood so-
dium decreased” would be all be represented by the preferred term
‘‘hyponatremia.” The majority of these mappings were accom-
plished by exact term matching or by stemming of terms. Manual
mapping was required in approximately 15% of cases.
Data in paragraph format required additional manual curation.
Paragraphs were ﬁrst grouped as either organ system-based side-
effect lists or unspeciﬁed side-effect lists. Those arranged by organsystem followed a generally consistent format, displaying a cate-
gory name followed by frequent, infrequent, and rare events. Based
on this pattern, we used regular expressions to parse these para-
graphs into side-effect terms and corresponding frequencies.
Unspeciﬁed lists were more challenging in that they comprised a
wide variety of formats. For example, one paragraph began, ‘‘The
following events occurred in >2% of patients. Events shown in ital-
ics occurred in >5% of patients.” In this case, we had to separate
normal from italicized text and manually assign the appropriate
frequency values. Given such idiosyncratic formats, careful label
review and data entry was essential. This manual effort resulted
in a lengthy extraction process, with an average of 1.25 h per label.
2.3. Development of a frequency scoring system
In order to standardize the extracted frequencies from multiple
labels, we devised a scoring system by which the relationship be-
tween each drug and associated side-effect could be represented
using a single numeric value. This value was known as the Rxplore
Score and was calculated using algorithms developed by the
authors and based upon expert consensus and review of term
use across multiple labels (examples shown in Table 1). The algo-
rithms covered a broad range of frequency reporting formats, rang-
ing from precise drug versus placebo incidence rates to vague
phrases such as ‘‘may sometimes occur.” In total, 39 different algo-
rithms were required for the describe all the frequency relation-
ships found in our set of 250 labels. Our algorithms required
iterative modiﬁcation as new labels were introduced. Thus, the ori-
ginal text-based frequency descriptors (e.g., ‘‘occurred rarely”)
were also retained in the database so that scores could be recalcu-
lated in the event of an algorithm modiﬁcation.
A common challenge in implementing our scoring system was
the presence of reactions which were listed multiple times in a sin-
gle label. For example, the label of a selective serotonin reuptake
inhibitor might include clinical trials for both depression and anx-
iety, but report very different rates of nausea in one population
than the other. Alternatively, a given side-effect might occur in a
high percentage of patients during a controlled trial but be re-
ported as ‘‘rare” in post-marketing reports. To ensure consistency
in our system, we used the following preferences to prioritize
which report type would serve as the source for the Rxplore Score
calculation: placebo-controlled clinical trial over post-marketing
report; larger trial over smaller trial; longer trial over shorter trial;
and trial for primary indication over trial for secondary indication.
Upon completion of the SPL extraction and standardization pro-
cess, the knowledgebase contained information on 16,340 distinct
medication and side-effect pairs. See Table 2 for a summary of the
knowledgebase development process.
2.4. Design of the visualization tool
The Rxplore Score, though simplistic in nature, facilitated the
development of a visual interface for representing adverse reaction
data at both an overview and detailed level. Our browser-based
application allows the user to enter a list of patient medications.
Upon entry of the ﬁrst medication, the system displays a horizontal
bar graph showing the drug’s most common side-effects; bar
lengths are proportional to the calculated Rxplore Score for each
effect (Fig. 1A). With each new medication the graph is recalcu-
lated to display the most common side-effects of the collective reg-
imen as determined by the summation of Rxplore Scores (Fig. 1B).
To see more detailed adverse reaction data for a particular drug
and side-effect combination, the user moves the mouse to the
appropriate location on the graph (Fig. 1B). The results can be ﬁl-
tered in several ways: by organ system, by therapeutic class, or
by direct search for a speciﬁc side-effect of interest. Each medica-
Table 3
Clinical scenarios used in Rxplore Study.
Patient 70 year-old male with hypertension,
congestive heart failure, and hyperlipidemia
Medications Atorvastatin, amlodipine, atenolol, furosemide, ﬂuoxetine
Adverse reactions Alopecia, tremor, ﬂushing, erythema multiform
Patient 64 year-old female with diabetes, GERD,
osteoporosis, and mild cognitive impairment
Medications Rosiglitazone, glimepiride, alendronate, donepezil,
pantoprazole
Adverse reactions Pruritus, hyponatremia, ﬂatulence, photosensitivity
Table 1
Example algorithms for Rxplore Scores.
Frequency Descriptor Algorithm Rxplore score
Seen in 27% of patients on
drug and 12% on placebo
Drug%–Placebo% 27–12 = 15
Occurred in 3% (Low) to 9% (High)
of patients
Low+(HighLow)/2 3+(93)/2 = 6
Occurred ‘‘rarely” Expert consensus 0.
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DailyMed [15].2.5. Evaluation study
We conducted a pilot study comparing the speed and accuracy
of Rxplore in retrieving adverse reaction data to that of UpToDate,
a popular clinical information resource. The subjects were 24 phy-
sicians in residency training in internal medicine or family practice
at Indiana University. All subjects had prior experience using
UpToDate.
Subjects were given a 3-min orientation to both Rxplore and
UpToDate. For each system, the retrieval of adverse reaction data
for two drugs was demonstrated. Following this orientation, the
subjects were presented with two sample clinical tasks consisting
of a patient description, a medication list, and four hypothetical ad-
verse reactions (Table 3). For each reaction, the subjects were
asked one of the following: which of the patient’s drugs are knownFig. 1. Results display in Rxplore. (A) The most common reactions seen with Zo
Table 2
Creation of the quantitative adverse reaction knowledgebase.
Step Process details
Medication selection Identiﬁed 250 commonly prescribed medications based on n
dispensing data
SPL extraction Retrieved Structure Product Label for each drug. Extracted s
Data standardization Standardized side-effects to MedDRA preferred terms. Stand
simpliﬁed numeric value (Rxplore Score).
Storage in
knowledgebase
Stored drug name, coded effect, and Score for 16,340 drug-eto cause this reaction; or which one drug is most likely to cause
this reaction. To answer these questions, the subjects were ran-
domly assigned to use either Rxplore or UpToDate. They were al-
lowed to use any method of searching or ﬁltering for information
provided by these sites. The resource was switched between tasks
so that all subjects answered questions using both systems. The or-
der of tasks and order of questions within each task were
randomized.
For each question, the subject’s answer and time to completion
were recorded. Data on task order, question order, and resource or-
der were also stored. The authors veriﬁed that answers to all ques-
tions were available and identical in both resources. After ﬁnishing
the tasks, subjects completed an online survey regarding their
experience using Rxplore. The survey consisted of six questions
generated by the authors addressing the clinical utility and speed
of Rxplore as well as overall user satisfaction.loft alone. (B) The most common ‘‘combined” effects of a six drug regimen.
Example
ational and local pharmacy Lisinopril
ide-effect and frequency data ‘‘Taste disturbances occurred rarely in
patients on Lisinopril”
ardized frequency data to a ‘‘Taste Disturbance”? ‘‘Dysgeusia”
‘‘Rarely”? 0.3
ffect pairs Lisinopril|Dysgeusia|0.3
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the average task-wise time between the two software tools, and
our alternative hypothesis was that Rxplore would entail less time
to complete a task than UpToDate. Study subjects were blinded to
this hypothesis and were unaware that measurements of time and
accuracy were being recorded. In order to account for intra-subject
correlation (i.e., the relationship between an individual subject’s
performance on each of the two tasks), we analyzed time to answer
using mixed models and we used generalized estimating equations
to evaluate answer accuracy.
3. Results
3.1. Accuracy of answers independent of time
Physicians using Rxplore answered 78% (95% CI [65, 87]) of
questions correctly, compared with 70% (95% CI [57%, 80%]) ques-
tions correct by those using UpToDate (p = 0.27). The order of the
clinical tasks and order of individual questions within each task
did not affect accuracy.
3.2. Time to answer
When using Rxplore, clinicians answered questions in signiﬁ-
cantly less time than with UpToDate. The mean time per question
regardless of accuracy was 61 s (95% CI [46, 77]) for Rxplore versus
155 s (95% CI [138, 171]) for UpToDate (p < 0.0001) (Fig. 2). The
mean time to complete a four-question task using Rxplore was
239 s (95% CI [174, 304]) compared with 625 s (95% CI [553,
698]) using UpToDate (p < 0.001).
Correct answers were also obtained in signiﬁcantly less time
using Rxplore. The average time to a correct answer was 62 s
(95% CI [46, 79]) for Rxplore and 160 s (95% CI [142, 179]) for
UpToDate (p < 0.0001).
As evident in Fig. 2, outliers requiring 200 s or more to answer a
question were found in both groups. To assess the impact of these
outliers, we repeated answer time calculations using median
rather than mean times. Statistical trends remained consistent.
The median time per question regardless of accuracy was 39 s
(95% CI [31, 49]) for Rxplore versus 142 s (95% CI [122, 163]) for
UpToDate. Correct answers were reached in a median time ofFig. 2. Mean time to assess a ﬁve drug regimen for possible causes of an adverse
reaction.37 s (95% CI [29, 47]) with Rxplore compared with 159 s (95% CI
[137, 206]) for UpToDate. Median four-question task time was
228 s for Rxplore (95% CI [193, 262]) versus with 602 s (95% CI
[534, 678]) for UpToDate.
3.3. Time to answer by question order
For both systems, question order had a statistically signiﬁcant
impact on time to answer. Subjects required more time to com-
plete the ﬁrst question in a given task, regardless of the question’s
content (p < 0.0001 for Rxplore, p = 0.003 for UpToDate). For
Rxplore, ﬁnding a correct answer took an average of 145 s for the
ﬁrst question, while questions 2, 3, and 4 were answered correctly
in 42, 33, and 30 s, respectively. With UpToDate, this differential
was less pronounced but still present. Correct answers took 212 s
for question one, followed by 143, 133, and 155 s for the ﬁnal three
questions in a task.
3.4. Survey results
23/24 subjects completed the survey. Respondents showed a
very favorable impression of Rxplore, with 100% describing their
overall experience as good or excellent, and 100% stating they
would be likely or very likely to use Rxplore again. All respondents
rated Rxplore as faster than or much faster than their current drug
information resource.4. Discussion
In this paper, we described the development of a decision sup-
port system for the evaluation of adverse reactions in patients on
multiple medications. Use of this system resulted in a 60% reduc-
tion in the time required to research medication side-effects when
compared with a traditional drug information resource. This in-
creased speed was achieved with no decrease in accuracy. Further-
more, physicians rated the application very highly in terms of
usability and overall satisfaction.
Reducing adverse drug events is a national mandate, yet physi-
cians face increasing time pressures that limit their ability to per-
form thorough medication reviews [1,11]. Thus, technological
innovations are necessary to maximize patient safety while main-
taining physician efﬁciency. Rxplore, which signiﬁcantly decreases
the time required to review adverse drug reactions, may be an
example of such innovation, and it is worth considering which par-
ticular design elements were most responsible for its success.
4.1. Key system design features
Simultaneous lookup of multiple medications is an essential
component of Rxplore. As discussed earlier, multi-drug lookup
has been used in numerous applications for the identiﬁcation of
drug–drug interactions. Yet it had not previously been extended
to other types of drug information. In this study, we demonstrated
its effectiveness in evaluating adverse reactions. We believe it
could also be successfully applied to drug contraindications, preg-
nancy safety categories, formulary status, and other commonly
cross-referenced information. The volume of data produced by
multiple medication lookup can be signiﬁcant, however, and effec-
tive ﬁlters are essential. In Rxplore, we provide the user with a
means to view side-effects by overall frequency, by organ system,
or by speciﬁc name. These ﬁlters may prevent the user from being
overwhelmed by the data and facilitate rapid retrieval of the ef-
fects of interest.
Another principle design feature of Rxplore is the use of infor-
mation visualization to present the query results. Studies have
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support the extraction of useful information from complex medical
data [14,16,17]. By shifting workload from the cognitive to percep-
tual system, the subject is able to interact with the data at a higher
level, expending less effort on remembering discrete bits of infor-
mation than on interpreting their meaning [18]. In Rxplore, all re-
sults are shown on a single page, meaning that the user does not
need to write down or remember information in order to make
comparisons between drugs. Furthermore, by using standard bar
graphs and tooltips for detailed data, we have created visualiza-
tions that are intuitive to use and require no prior training.
In sum, the increased efﬁciency seen with Rxplore is likely
attributable to a combination of simultaneous multi-data retrieval,
rapid ﬁltering, and intuitive visual results. These elements, when
taken together, form a process which may offer beneﬁt in other
clinical information tasks, such as review of laboratory results,
selection of diagnostic tests, and narrowing of differential diagno-
ses. The common factor in these cognitive processes is that they re-
quire the physician to consider and compare multiple data points,
retain the acquired knowledge for at least several minutes, and
make a decision once all elements have been reviewed. They are
thus susceptible to the inefﬁciencies of looking up multiple items
and to gaps in physician concentration and working memory.
Our results with Rxplore suggest that these limitations can be ame-
liorated by (1) initial retrieval of a large dataset containing all or
most of the elements to be reviewed (e.g. all patient laboratory
tests); (2) ﬁltering the data by a user-selected dimension of inter-
est (e.g. test frequency); (3) visualization showing the relationship
among the multiple elements according to the stated parameter
(e.g., word cloud of patient labs sized by frequency). A prerequisite
to these steps is data model standardization. In the example of a
laboratory results viewer, all test names and units would need to
be harmonized in advance (preferably using a terminology such
as LOINC) in order for the system to deliver data in a consolidated
form. While each application requires its own customization and
choice of data model, this three-step process, if applied correctly,
has the potential to yield efﬁciency gains.
4.2. Speed variability based on question order
A notable ﬁnding of our study was the signiﬁcant difference be-
tween time to answer the ﬁrst question in a patient scenario and
time to answer subsequent questions. This pattern was seen with
both Rxplore and UpToDate, and may in part be explained by
increasing familiarity with these systems over the course of
answering four questions. But with Rxplore, a likely additional fac-
tor is that users must ﬁrst type in each of the patients’ medications
in order to answer the initial question in a task. But for follow-up
questions on the same patient, they can simply ﬁlter the existing
results. With answer times averaging over 100 s faster for the latter
questions, we suspect that medication entry is a signiﬁcant bottle-
neck in Rxplore. Thus, Rxplore’s speed gains may be improved even
further through automatic pre-population of the medication list
from an electronic medical record via web service or standards-
based CDS integration approach such as InfoButtons [19]. This step
would eliminate the need for manual entry of drugs. More impor-
tantly, it would potentially allow physicians to answer any adverse
reaction query—regardless of number of drugs involved—in less
than 40 s. We would thus achieve our goal of bringing the time re-
quired to perform a medication review down to a level acceptable
to physicians and practicable in busy clinical settings.
4.3. Limitations
Our system does have a few limitations. The Rxplore algorithms
were designed to apply a consistent metric across a wide variety ofqualitative and quantitative data, and are thus not precise mea-
sures of side-effect frequency. Validation studies are currently
underway to assess and reﬁne these algorithms through compari-
son of Rxplore-predicted frequencies with those reported in large
pharmacosurveillance datasets such as MedWatch. Such validation
efforts are necessarily limited, however, by the lack of a true ‘‘gold
standard” in deﬁning the incidence rates of adverse drug events.
Nonetheless, we expect that iterative improvement of algorithms,
particularly with respect to the synergistic or interacting effects
of multiple drugs, will enhance both the efﬁciency of our system
and physicians’ conﬁdence in its use.
A second issue is the difﬁculty of building and maintaining a
comprehensive adverse reaction database based on FDA labels. A
successful drug information system requires data on a broad array
of commonly used medications and these data must be updated
regularly. Our method of extracting adverse events, incorporating
both manual and automated processes, was time-consuming and
unlikely to scale well. Available vendor-based drug compendia,
while comprehensive, do not contain frequency data at the level
of granularity required by our system. Thus, to successfully imple-
ment Rxplore in the clinical setting we must create a more fully
automated mechanism of extracting side-effect information from
the Structured Product Label (SPL). Challenges to developing such
a system include the SPL’s lack of standard terminology for
describing adverse events (e.g., MedDRA, SNOMED-CT) and incon-
sistencies in its tabular and text formats. Despite these challenges,
we are currently underway in building such a system and creating
a full-scale implementation of Rxplore.
In regards to our evaluation study, it was performed in a con-
trolled environment and therefore may not account for the unpre-
dictable nature of the clinical setting. Furthermore, our study used
sample clinical scenarios designed by the authors and limited in
scope to those drugs currently available in Rxplore. While we ex-
pect the application’s efﬁciency to be maintained across a broad
range of medications, it is possible that selecting a different combi-
nation of medications for our tasks would have yielded different
results. Additionally, we chose UpToDate as our comparator
based on its popularity among practicing physicians and the level
of detail provided by its drug monographs; however, other systems
such as ePocrates or DailyMed might have yielded different re-
sults. Finally, our study’s endpoints were speed and accuracy of an-
swers, not of medical decision-making. Thus, further studies are
necessary to determine Rxplore’s potential impact on patient out-
comes and adverse drug events.5. Conclusion
The combination of multi-drug lookup and data visualization
can reduce the time required to review potential adverse reactions.
At a broader level, this process of high-volume information retrie-
val, ﬁltering, and visualization may extend beyond medications to
other domains of clinical decision support. To successfully apply
this technique, however, the underlying data must be properly
structured and standardized so that concise visualizations are
possible.
Our future work includes validation and reﬁnement of Rxplore’s
scoring algorithms, expanded task analysis and assessment of
alternate visualization schemes, integration into a computerized
order entry system, and evaluation of the application’s impact on
adverse drug events in the clinical setting.Acknowledgments
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